Brandes A A, Pasetto L M, Monfardini S
Divisione di Oncologia Medica, Azienda Ospedale, Università, Padova, Italia.
Anticancer Res. 2000 May-Jun;20(3B):1913-20.
The incidence of Central Nervous System (CNS) neoplasias ranges from 3.8 to 5.1 cases per 100,000 inhabitants. In the presence of recurrence, the treatment is problematic; chemotherapy is experimental, primarily because the response is palliative and of limited duration.
This article analyzes the new drugs that have been introduced for the treatment of these patients in recent years, the objective response, the TTP and the MST.
The most encouraging results to date come from studies of temozolomide, which is one of the most active and best tolerated drugs in recent years.
New approaches to chemotherapy treatment are necessary. Enrollment of patients into rigorous, well-conducted, clinical trials, both at tumor diagnosis and after tumor recurrence, will generate new information regarding investigational therapies and may offer improved therapies for patients with malignant gliomas.
中枢神经系统（CNS）肿瘤的发病率为每10万居民3.8至5.1例。出现复发时，治疗存在问题；化疗是试验性的，主要原因是其反应是姑息性的且持续时间有限。
本文分析了近年来用于治疗这些患者的新药、客观反应、无进展生存期（TTP）和总生存期（MST）。
迄今为止最令人鼓舞的结果来自替莫唑胺的研究，它是近年来活性最强且耐受性最佳的药物之一。
化疗治疗需要新的方法。在肿瘤诊断时以及肿瘤复发后，让患者参加严格、开展良好的临床试验，将产生有关研究性疗法的新信息，并可能为恶性胶质瘤患者提供更好的治疗方法。
